2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134937
    BC8-15 950385-77-0 98%
    BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.
    BC8-15
  • HY-134950
    (E)-C-HDMAPP ammonium 933030-60-5 98%
    (E)-C-HDMAPP ammonium, is a potent phosphoantigen in ammonium form as well as a pyrophosphonate form of (E)-HDMAPP. (E)-C-HDMAPP is also an effective activator of γδ-T cells, induces T-cell stimulatory responses in vitro (EC50=0.91 nM for TNF-α release).
    (E)-C-HDMAPP ammonium
  • HY-134958
    Polyinosinic-polycytidylic acid potassium 31852-29-6 98%
    Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis.
    Polyinosinic-polycytidylic acid potassium
  • HY-13496A
    JNJ-28312141 hydrochloride 1149939-55-8 98%
    JNJ-28312141 hydrochloride is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 hydrochloride inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 hydrochloride exhibits anti-inflammatory activity in mouse arthritis model.
    JNJ-28312141 hydrochloride
  • HY-134998
    Oltipraz metabolite M2 84201-40-1 98%
    Oltipraz metabolite M2, an active metabolite of Oltipraz (HY-12519), is an orally active HIF-1α inhibitor. Oltipraz metabolite M2 increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK in high-fat diet (HFD)-fed mice. Oltipraz metabolite M2 can be used for hepatic steatosis and steatohepatitis research.
    Oltipraz metabolite M2
  • HY-135089
    Autotaxin-IN-5 2156655-99-9 98%
    Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis.
    Autotaxin-IN-5
  • HY-13511S
    Rupatadine-d6 D-tartrate 98%
    Rupatadine-d6 (D-tartrate) is deuterated labeled Rupatadine (HY-13511). Rupatadine (UR-12592) is a potent, orally active and long-lasting dual PAF/H1 antagonist, with Kis of 0.55 μM and 0.1 μM, respectively. Rupatadine can be used for the research of allergic rhinitis and urticaria.
    Rupatadine-d6 D-tartrate
  • HY-135181
    Daunosamnyl-daunorubicin 28008-54-0 98%
    Daunosamnyl-daunorubic, an antibiotic, can bind calf thymus DNA.
    Daunosamnyl-daunorubicin
  • HY-135284
    FTY720-Mitoxy 1604816-11-6 98%
    FTY720-Mitoxy is a fingolimod hydrochloride (HY-12005) derivative with neuroprotective and PP2A activating activities. FTY720-Mitoxy has the property of targeting mitochondria. In addition, FTY720-Mitoxy protects neurons by reducing inflammatory responses and is used in the study of neurodegenerative diseases such as Parkinson's disease.
    FTY720-Mitoxy
  • HY-135288
    L-649923 114370-57-9 98%
    L-649923 is an orally active CysLT1 antagonist. L-649923 reduced the incidence of gastritis in an animal model of acute gastric mucosal injury. L-649923 can be used in research on diseases such as asthma and gastritis.
    L-649923
  • HY-135301
    Flavanone hydrazone 1692-46-2 98%
    Flavanone hydrazine is a potent non-steroidal anti-inflammatory agent. Flavanone hydrazine effectively inhibits lens protein-induced ocular inflammation.
    Flavanone hydrazone
  • HY-135373
    Desfluoro-atorvastatin 433289-84-0 98%
    Desfluoro-atorvastatin is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.
    Desfluoro-atorvastatin
  • HY-135374
    (3R,5S)-Atorvastatin sodium 131275-93-9 98%
    (3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    (3R,5S)-Atorvastatin sodium
  • HY-135375
    O-Methyl Atorvastatin calcium 887196-29-4 98%
    O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.
    O-Methyl Atorvastatin calcium
  • HY-135382
    PROTAC IRAK4 degrader-2 2374122-27-5 98%
    PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC50 in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC50 of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs.
    PROTAC IRAK4 degrader-2
  • HY-135386
    5β-​Dutasteride 957229-52-6 98%
    5β-Dutasteride is the S configuration of Dutasteride. 5β-Dutasteride is a potent inhibitor of both 5 alpha-reductase isozymes.
    5β-​Dutasteride
  • HY-135408
    Trimetazidine-N-oxide 1644530-89-1 98%
    Trimetazidine-N-oxide is the major active metabolite of Trimetazidine. Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM. Trimetazidine is an effective antianginal agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties.
    Trimetazidine-N-oxide
  • HY-135413
    MeCY5-NHS ester 937739-58-7
    MeCY5-NHS estera is a reactive dye. MeCY5-NHS estera can be used for the labeling of proteins and nucleic acids.
    MeCY5-NHS ester
  • HY-135495
    AM-0466 1642113-59-4 98%
    AM-0466 is a sodium channel inhibitor with nanomolar levels of NaV1.7 inhibitory activity. AM-0466 exhibits potent pharmacodynamic activity in a NaV1.7-dependent histamine-induced itch model. AM-0466 also showed significant analgesic effects in capsaicin-induced pain models. After optimizing its pharmacokinetic properties, AM-0466 was advanced into in vivo targeting and efficacy models for testing.
    AM-0466
  • HY-135511
    Nor-Cerpegin 145887-88-3 98%
    Nor-Cerpegin is an analog of Cerpegin. Cerpegin, a pyridinone-fused c-lactone, is an inhibitor of 20S proteasome. Cerpegin can be used as a tranquillizer, anti-inflammatory, analgesic and antiulcer.
    Nor-Cerpegin
Cat. No. Product Name / Synonyms Application Reactivity